Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug | ||
Journal of Advanced Biomedical and Pharmaceutical Sciences | ||
Article 2, Volume 7, Issue 1, January 2024, Pages 18-25 PDF (637.74 K) | ||
Document Type: Original Article | ||
DOI: 10.21608/jabps.2023.234602.1202 | ||
Authors | ||
Mahmoud EL-Badry* 1; Ominia Ali Mahmoud2; Dina Fathalla3; Gamal EL-Gendy4 | ||
1Dept of Pharmaceutics Faculty of Pharmacy Assiut University | ||
2Department of pharmaceutics, Faculty of pharmacy, Sohag University | ||
3Faculty of Pharmacy, Assiut university | ||
4Department of Pharmaceutics, Faculty of pharmacy, Assiut University | ||
Abstract | ||
Abstract Velpatasvir (VLP) as, a medication used to treat hepatitis-C virus (HCV). It has a very low oral bioavailability (25%). The aim of the current work is to prepare VLP loaded nanostructured lipid carriers (VLP-NLCs) as a potential way to enhance VLP aqueous solubility and bioavailability and increase its efficacy. The preparation of VLP-NLCs was carried out using the emulsification - solvent evaporation method, followed by ultrasonication. The prepared nanocarrier was examined for its particle size, zeta potential, entrapment efficiency and in-vitro drug release of the selected formula. VLP-NLCs displayed narrow size distribution, spherical morphologies that were nanosized (105 ± 2.3 nm), and significant drug entrapment efficiencies (> 80%). Particle size ranged between 105 ± 2.3 to 1399 ± 2.8 nm and zeta potential between -14.6 ± 0.2 to -46.0 ± 1.1 mV. High entrapping efficiency was obtained due to incorporation of liquid lipid. The In Vitro release showed prolonged time dependent release. NLC 6 had the best results among the eight prepared formulae. These findings show that NLC is a potential carrier to improve the solubility of drug and enhance its bioavailability. | ||
Keywords | ||
Velpatasvir; HCV; Nanostructured lipid carriers (NLCs); particle size; in-vitro drug release | ||
Statistics Article View: 353 PDF Download: 485 |